1. Home
  2. WYY vs ACET Comparison

WYY vs ACET Comparison

Compare WYY & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WidePoint Corporation

WYY

WidePoint Corporation

HOLD

Current Price

$5.05

Market Cap

68.2M

Sector

Technology

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$7.19

Market Cap

69.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WYY
ACET
Founded
1991
1947
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.2M
69.6M
IPO Year
2005
2017

Fundamental Metrics

Financial Performance
Metric
WYY
ACET
Price
$5.05
$7.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$8.67
$56.00
AVG Volume (30 Days)
33.1K
112.4K
Earning Date
01-01-0001
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
54.35
N/A
EPS
N/A
N/A
Revenue
$142,571,749.00
N/A
Revenue This Year
$5.20
N/A
Revenue Next Year
$15.39
N/A
P/E Ratio
N/A
N/A
Revenue Growth
34.47
N/A
52 Week Low
$2.19
$0.45
52 Week High
$7.55
$9.05

Technical Indicators

Market Signals
Indicator
WYY
ACET
Relative Strength Index (RSI) 52.39 43.92
Support Level $3.96 $6.54
Resistance Level $5.90 $8.34
Average True Range (ATR) 0.29 0.44
MACD 0.12 -0.07
Stochastic Oscillator 73.54 10.23

Price Performance

Historical Comparison
WYY
ACET

About WYY WidePoint Corporation

WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: